-
PX-478 2HCl: Better HIF-1α Assay Design
2026-09-30
PX-478 2HCl is a versatile HIF-1α inhibitor for connecting hypoxia biology with functional assay design. This guide interprets prenatal hypoxia findings while developing a practical framework for cancer cell line hypoxia studies, radiosensitization, and in vivo validation.
-
ABT-263 (Navitoclax): Practical Assay Guide
2026-09-29
This guide explains how to prepare, dose, and quality-control ABT-263 (Navitoclax), SKU A3007, for apoptosis and cancer biology workflows when no directly matched paper evidence is available. It is intended for research assays and model development, not diagnostic, therapeutic, or medical use.
-
Triamcinolone: Practical Research Workflow
2026-09-29
Triamcinolone is a synthetic glucocorticoid agonist for controlled in vitro studies of glucocorticoid signaling, inflammation, and immunosuppression. This guide covers solvent selection, stock handling, controls, and assay QC; the compound is not intended for diagnostic, therapeutic, or clinical use.
-
BHPF Inhibits GPER Signaling in Neuroblastoma Cells
2026-09-28
A 2024 study identifies fluorene-9-bisphenol (BHPF) as a likely inhibitor of GPER and maps receptor residues involved in its recognition. Combining molecular modeling with receptor perturbation and cell-based assays, the work links BHPF binding to reduced GPER signaling and apoptosis-related effects in human neuroblastoma cells.
-
Propranolol Reprograms Burn-Associated Metabolism
2026-09-27
A phase II randomized trial linked propranolol treatment after severe burns to shifts in adipose-tissue metabolism and a less inflammatory lipid profile. Its integrated metabolomic, lipidomic, and molecular analyses offer mechanistic clues about hypermetabolism, while leaving clinical outcome effects and the pathway-level causes to be tested further.
-
Triamcinolone B1859: Research Workflow and QC
2026-09-26
Triamcinolone B1859 provides a defined synthetic glucocorticoid agonist for controlled studies of glucocorticoid signaling, inflammation, and immunosuppression. Use it in research assays with a matched solvent control and experimentally established treatment conditions; it is not for diagnostic, therapeutic, or clinical use.
-
Dabigatran: Evidence for Thromboembolism Prevention
2026-09-26
Enriquez and colleagues reviewed clinical evidence for dabigatran, an oral direct thrombin inhibitor, across atrial fibrillation, orthopedic venous thromboembolism prevention, and treatment of acute venous thromboembolism. The review highlights indication-specific efficacy, predictable pharmacology, renal clearance, and bleeding-management considerations, while emphasizing that its conclusions reflect evidence available in 2015.
-
HyperScript RT SuperMix for qPCR in NAFLD Research
2026-09-25
Connects a published PINK1/Park2 mitophagy study to a practical two-step qRT-PCR workflow for liver gene-expression experiments. The premixed formulation is especially useful when RNA is scarce or transcripts are structurally challenging, while the article distinguishes product specifications from suggested starting conditions.
-
Ionophore Toxicity in Animals: Key Mechanisms
2026-09-25
Ekinci, Chłodowska, and Olejnik review how polyether ionophores used to control poultry coccidiosis can cause toxicity, with risk shaped by dose, animal species, and age. Their synthesis connects disrupted ion balance with impaired oxidative phosphorylation and injury to skeletal and cardiac muscle, while emphasizing that molecular pathways and cross-species differences remain incompletely resolved.
-
SAR131675: VEGFR-3 Inhibitor Workflows
2026-09-24
Use SAR131675 to probe VEGFR-3-dependent lymphatic endothelial survival, migration, and tumor-associated lymphangiogenesis with nanomolar potency. This workflow-focused guide pairs pathway readouts with practical solubility controls and clear limits on what the evidence supports.
-
Bradykinin BA5201: Practical Assay Workflow
2026-09-24
Bradykinin BA5201 is a defined peptide reagent for studying endothelium-dependent vasodilation, vascular permeability modulation, tissue-specific smooth muscle responses, and pain or inflammation-related endpoints. Use it in controlled research assays—not for diagnosis or medical use—and prepare solutions for prompt use rather than long-term storage.
-
RNAi Screen Identifies Rab11a-Linked SARS-CoV-2 Release
2026-09-23
Kerr et al. used an arrayed, druggable-genome RNAi screen with two-timepoint viral RNA measurements to identify host factors acting across the SARS-CoV-2 replication and reinfection cycle. The study highlights Rab11a-dependent vesicular transport as a conserved proviral pathway and shows that pharmacological inhibition of CDK9-linked cargo delivery can prevent viral release.
-
Zoledronic Acid: A Mechanism-First Assay Guide
2026-09-23
Zoledronic Acid is a nitrogen-containing bisphosphonate used to investigate cancer-cell apoptosis and osteolytic disease. This mechanism-first guide connects assay design with a 2026 immunometabolic study while clearly separating validated evidence from hypothesis-generating applications.
-
Triamcinolone B1859: Practical Research Guide
2026-09-22
Triamcinolone B1859 provides a defined synthetic glucocorticoid agonist for controlled in vitro studies of glucocorticoid signaling, inflammation, and immunosuppression. This guide addresses solvent selection, stock preparation, storage, assay controls, and interpretation boundaries; the material is for scientific research only and is not intended for diagnostic, therapeutic, or clinical use.
-
Sunitinib Workflows for RCC Angiogenesis Research
2026-09-21
Build reproducible Sunitinib experiments around RTK signaling, angiogenesis, apoptosis, and resistance in renal cell carcinoma models. This workflow connects practical assay design with recent evidence that glycolysis inhibition can restore sensitivity to this multi-targeted inhibitor.